Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Tuspetinib is a convenient once daily oral agent, and the TUS+VEN+AZA triplet has the potential to treat the larger AML population in a mutation agnostic manner, not just narrow subpopulations.

AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Responses to TUS were also observed in those with prior-VEN and prior-FLT3 inhibitor (FLT3i) therapies ...

1St. Jude Children's Research Hospital, Memphis, TN.

The 2024 ELN risk stratification was developed with evidence from an exploratory analysis of pooled data from the phase 3 VIALE-A trial and a phase 1 b study of azacitidine plus venetoclax.

The company's focus on targeted therapies for specific genetic mutations in AML, such as KMT2A rearrangements and NPM1 mutations, could provide a competitive edge in a market that is increasingly ...